Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study
| Autor: | Stanley P. Balcerzak, Stephen K. Williamson, I Gill, M E Marshall, Robert B. Livingston, James K. Weick, Steven M. Grunberg, John Crowley, Thomas J. Braun, T O'Rourke |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms Cyclophosphamide medicine.medical_treatment Administration Oral Gastroenterology Drug Administration Schedule Oral administration Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Lung cancer Survival rate Etoposide Aged Aged 80 and over Chemotherapy Leukopenia business.industry Middle Aged medicine.disease Survival Analysis Surgery Regimen Treatment Outcome Oncology Female medicine.symptom business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 11:1598-1601 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1993.11.8.1598 |
| Popis: | PURPOSE We designed an all-oral regimen of etoposide and cyclophosphamide for use in advanced non-small-cell lung cancer. PATIENTS AND METHODS Eligible patients were chemotherapy-naive and had histologically confirmed assessable or measurable stage IV non-small-cell lung cancer. Patients received etoposide 50 mg/m2/d orally days 1 through 14 and cyclophosphamide 50 mg/m2/d orally days 1 through 14 every 28 days. Doses on later cycles were adjusted for myelosuppression. RESULTS Sixty-six patients (64 eligible patients) received 192 cycles of oral extended etoposide/cyclophosphamide therapy (median, two cycles; range, zero to 15). Therapy was well tolerated with the mean dose per cycle being 104% of the originally scheduled dose. Two patients (3%) achieved a complete response and six (9%) achieved a partial response. Leukopenia, anemia, nausea/vomiting, and alopecia were the most common toxicities. Median survival was 6 months, and the 1-year survival rate was 25.6%, comparable to more intensive treatments. CONCLUSION Oral extended etoposide/cyclophosphamide is a well-tolerated alternative for the treatment of stage IV non-small-cell lung cancer and can be used as a basis for the design of further outpatient regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|